ArticleFrontiers in pharmacology2018
Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.Investigational new drugs · 2025Article
- CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3β-PD-L1 axis.Heliyon · 2024Article
- Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.Journal of the National Cancer Institute · 2023Article
- CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta.Frontiers in cell and developmental biology · 2023Article
- Review
- Adenosine signaling: Optimal target for gastric cancer immunotherapy.Frontiers in immunology · 2022Review
- CD38 in the age of COVID-19: a medical perspective.Physiological reviews · 2021Review
- The Circular Life of Human CD38: From Basic Science to Clinics and Back.Molecules (Basel, Switzerland) · 2020Review
- Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.Journal for immunotherapy of cancer · 2020Article
- Targeting Immunometabolism Mediated by CD73 Pathway inFrontiers in immunology · 2020Review
- CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.Frontiers in immunology · 2019Review
- Purinergic Profiling of Regulatory T-cells in Patients With Episodic Migraine.Frontiers in cellular neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine-induced killer (CIK) cells, a heterogeneous T cell population obtained by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.